These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 17442659

  • 21. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G, Kriegman A, Gonçalves J, Kianifard F, Warren M, Simon JA.
    Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
    [Abstract] [Full Text] [Related]

  • 22. Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
    Binkley N, Silverman SL, Simonelli C, Santiago N, Kohles JD, Dasic G, Sunyecz JA.
    Osteoporos Int; 2009 Sep; 20(9):1595-601. PubMed ID: 19145396
    [Abstract] [Full Text] [Related]

  • 23. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
    Broom RJ, Hinder V, Sharples K, Proctor J, Duffey S, Pollard S, Fong PC, Forgeson G, Harris DL, Jameson MB, O'Donnell A, North RT, Deva S, Hanning FJ, Grey A, Findlay MP.
    Clin Genitourin Cancer; 2015 Feb; 13(1):50-8. PubMed ID: 25163397
    [Abstract] [Full Text] [Related]

  • 24. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Feb; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 25. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
    Diel IJ, Weide R, Köppler H, Antràs L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.
    Support Care Cancer; 2009 Jun; 17(6):719-25. PubMed ID: 19089462
    [Abstract] [Full Text] [Related]

  • 26. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.
    Nelson A, Fenlon D, Morris J, Sampson C, Harrop E, Murray N, Wheatley D, Hood K, Griffiths G, Barrett-Lee P.
    Trials; 2013 Oct 09; 14():325. PubMed ID: 24107437
    [Abstract] [Full Text] [Related]

  • 27. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
    Diel IJ, Kurth AH, Sittig HB, Meden H, Maasberg M, Sandermann A, Bergner R.
    Support Care Cancer; 2010 Oct 09; 18(10):1305-12. PubMed ID: 20151162
    [Abstract] [Full Text] [Related]

  • 28. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.
    Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R, HORIZON-PFT Research Group.
    J Bone Miner Res; 2009 Sep 09; 24(9):1544-51. PubMed ID: 19338427
    [Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.
    Support Care Cancer; 2005 Dec 09; 13(12):975-86. PubMed ID: 15871033
    [Abstract] [Full Text] [Related]

  • 30. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A, Morabito N, Basile G, Brancatelli S, Cucinotta D, Lasco A.
    J Clin Endocrinol Metab; 2013 May 09; 98(5):1911-5. PubMed ID: 23596142
    [Abstract] [Full Text] [Related]

  • 31. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
    Mishra A.
    J Postgrad Med; 2008 May 09; 54(3):237. PubMed ID: 18626181
    [No Abstract] [Full Text] [Related]

  • 32. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
    Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ.
    Cancer; 2001 Apr 01; 91(7):1191-200. PubMed ID: 11283917
    [Abstract] [Full Text] [Related]

  • 33. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Metabolism; 2015 Oct 01; 64(10):1291-7. PubMed ID: 26198440
    [Abstract] [Full Text] [Related]

  • 34. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY.
    Rheumatology (Oxford); 2013 Jun 01; 52(6):1058-69. PubMed ID: 23365149
    [Abstract] [Full Text] [Related]

  • 35. Bisphosphonates for breast cancer.
    Pavlakis N, Schmidt R, Stockler M.
    Cochrane Database Syst Rev; 2005 Jul 20; (3):CD003474. PubMed ID: 16034900
    [Abstract] [Full Text] [Related]

  • 36. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
    Zhao X, Xu X, Guo L, Ragaz J, Guo H, Wu J, Shao Z, Zhu J, Guo X, Chen J, Zhu B, Wang Z, Hu X.
    Breast Cancer Res Treat; 2010 Dec 20; 124(3):733-43. PubMed ID: 20882405
    [Abstract] [Full Text] [Related]

  • 37. Bisphosphonates and other bone agents for breast cancer.
    Wong MH, Stockler MR, Pavlakis N.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD003474. PubMed ID: 22336790
    [Abstract] [Full Text] [Related]

  • 38. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.
    Arthritis Rheum; 2006 Jun 15; 54(6):1838-46. PubMed ID: 16729277
    [Abstract] [Full Text] [Related]

  • 39. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
    Zhao X, Xu X, Zhang Q, Jia Z, Sun S, Zhang J, Wang B, Wang Z, Hu X.
    BMC Cancer; 2011 Sep 22; 11():403. PubMed ID: 21936956
    [Abstract] [Full Text] [Related]

  • 40. Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases.
    Luedders DW, Steinhoff J, Thill M, Rody A, Bohlmann MK.
    Anticancer Res; 2015 Mar 22; 35(3):1797-802. PubMed ID: 25750345
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.